Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Myelodysplastic Syndromes 17Multiple Myeloma 13Lymphoma, Non-Hodgkin 13Hodgkin Disease 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia, Lymphocytic, Chronic, B-Cell 10Myeloproliferative Disorders 9Melanoma 8Recurrence 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Biphenotypic, Acute 7Anemia, Refractory, with Excess of Blasts 7Lymphoma 6Leukemia 6Lymphoma, Mantle-Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Waldenstrom Macroglobulinemia 4Neuroblastoma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Juvenile 4Hematologic Neoplasms 4Colorectal Neoplasms 4Burkitt Lymphoma 4Uveal Melanoma 3Stomach Neoplasms 3Primary Myelofibrosis 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

pevonedistat 1ibrutinib 1fludarabine phosphate 1Specimen Handling 1Pharmacogenomic Variants 1Leukapheresis 1Cyclophosphamide 1Blood Component Removal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × fludarabine phosphate × 90 days × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡